Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
49.35
-0.17 (-0.34%)
May 28, 2026, 1:32 PM EDT - Market open
Spruce Biosciences Employees
Spruce Biosciences had 8 employees as of December 31, 2025. The number of employees decreased by 13 or -61.90% compared to the previous year.
Employees
8
Change
-13
Growth
-61.90%
Revenue / Employee
n/a
Profits / Employee
-$4,648,875
Market Cap
133.36M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | -13 | -61.90% |
| Sep 30, 2025 | 9 | -13 | -59.09% |
| Jun 30, 2025 | 9 | -13 | -59.09% |
| Mar 31, 2025 | 20 | -2 | -9.09% |
| Dec 31, 2024 | 21 | -8 | -27.59% |
| Sep 30, 2024 | 22 | -9 | -29.03% |
| Jun 30, 2024 | 22 | -10 | -31.25% |
| Mar 31, 2024 | 22 | -8 | -26.67% |
| Dec 31, 2023 | 29 | 2 | 7.41% |
| Sep 30, 2023 | 31 | 9 | 40.91% |
| Jun 30, 2023 | 32 | 15 | 88.24% |
| Mar 31, 2023 | 30 | 14 | 87.50% |
| Dec 31, 2022 | 27 | 12 | 80.00% |
| Sep 30, 2022 | 22 | 3 | 15.79% |
| Jun 30, 2022 | 17 | -4 | -19.05% |
| Mar 31, 2022 | 16 | -3 | -15.79% |
| Dec 31, 2021 | 15 | -2 | -11.76% |
| Sep 30, 2021 | 19 | 4 | 26.67% |
| Jun 30, 2021 | 21 | 6 | 40.00% |
| Mar 31, 2021 | 19 | 4 | 26.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Molecular Partners AG | 134 |
| Fractyl Health | 100 |
| Agenus | 81 |
| Connect Biopharma Holdings | 64 |
| Corbus Pharmaceuticals Holdings | 36 |
| Cardiff Oncology | 31 |
| Genelux | 26 |
| Black Diamond Therapeutics | 21 |
SPRB News
- 21 hours ago - Spruce Biosciences to Participate in Upcoming Conferences in June - Business Wire
- 7 days ago - Spruce Biosciences Transcript: AGM 2026 - Transcripts
- 14 days ago - Spruce Biosciences price target lowered to $150 from $170 at Citizens - TheFly
- 15 days ago - Spruce Biosciences reports Q1 EPS ($8.94), consensus ($6.11) - TheFly
- 15 days ago - Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Business Wire
- 15 days ago - Spruce Biosciences Earnings release: Q1 2026 - Filings
- 15 days ago - Spruce Biosciences Quarterly report: Q1 2026 - Filings
- 24 days ago - Spruce Biosciences appoints Brian Walls as VP, market access - TheFly